SOPH vs. VTYX, CADL, JSPR, IVVD, ADAP, BDTX, CRBU, MGTX, PSTX, and STRO
Should you be buying SOPHiA GENETICS stock or one of its competitors? The main competitors of SOPHiA GENETICS include Ventyx Biosciences (VTYX), Candel Therapeutics (CADL), Jasper Therapeutics (JSPR), Invivyd (IVVD), Adaptimmune Therapeutics (ADAP), Black Diamond Therapeutics (BDTX), Caribou Biosciences (CRBU), MeiraGTx (MGTX), Poseida Therapeutics (PSTX), and Sutro Biopharma (STRO). These companies are all part of the "medical" sector.
SOPHiA GENETICS (NASDAQ:SOPH) and Ventyx Biosciences (NASDAQ:VTYX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.
Ventyx Biosciences received 11 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. However, 72.73% of users gave SOPHiA GENETICS an outperform vote while only 49.09% of users gave Ventyx Biosciences an outperform vote.
SOPHiA GENETICS presently has a consensus target price of $8.00, indicating a potential upside of 76.21%. Ventyx Biosciences has a consensus target price of $21.75, indicating a potential upside of 359.83%. Given Ventyx Biosciences' higher possible upside, analysts clearly believe Ventyx Biosciences is more favorable than SOPHiA GENETICS.
31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 97.9% of Ventyx Biosciences shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Comparatively, 24.4% of Ventyx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Ventyx Biosciences had 3 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 6 mentions for Ventyx Biosciences and 3 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 0.49 beat Ventyx Biosciences' score of 0.28 indicating that SOPHiA GENETICS is being referred to more favorably in the media.
SOPHiA GENETICS has higher revenue and earnings than Ventyx Biosciences. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks.
SOPHiA GENETICS has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.
Ventyx Biosciences has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -113.71%. SOPHiA GENETICS's return on equity of -47.56% beat Ventyx Biosciences' return on equity.
Summary
SOPHiA GENETICS beats Ventyx Biosciences on 9 of the 17 factors compared between the two stocks.
Get SOPHiA GENETICS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SOPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SOPHiA GENETICS Competitors List
Related Companies and Tools
